Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.

Next Previous
Trial Profile

A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HDP 102 (Primary)
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Heidelberg Pharma Research

Most Recent Events

  • 24 Jun 2025 Status changed from planning to recruiting.
  • 29 Apr 2025 New trial record
  • 24 Apr 2025 According to Heidelberg Pharma AG media release, Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started,received all the necessary approvals to start the clinical trial and expects the dosing of the first patient shortly.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top